Press Releases

DSM Biomedical announces a joint collaboration with Dechra Limited for the license and distribution of devices that create isolated solutions of highly concentrated cells and / or platelets for use with horses and companion animals.

DSM Biomedical, the world’s unrivaled biomaterials expert and committed partner in driving sustainable innovation in healthcare, reports an important milestone in its partnership with a consortium of physicians and researchers from Maastricht UMC+ and Eindhoven University of Technology to reduce the severe complications scoliosis patients routinely suffer from corrective surgery.

DSM announces a collaboration with PBC Biomed, a medical device design and development company to jointly design and develop novel materials for medical devices. Initially, the agreement will focus on the development of bone adhesives through PBC Biomed's affiliate, Biomimetic Innovations, which could help to meet the need for safer, less invasive surgical procedures that are also more cost-effective.

Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye, and DSM Biomedical, Inc., a global solutions provider in biomedical science and regenerative medicine, today reported that they have expanded their collaborative research, development, and license agreement.

DSM announces a new approach for its Additive Manufacturing (AM) activities. By aligning all its AM activities within the Materials cluster and promoting a partnership approach, DSM can provide customers an open and flexible infrastructure. This will help customers to find exactly the right materials and production systems for their applications.

DSM Biomedical announces a novel braiding technology of DSM’s medical grade UHMWPE fibers, Dyneema Purity® fibers, for use in the design and construction of medical devices. The new constructions of Dyneema Purity fiber are available by means of a patented platform technology entitled “IMPLANTABLE HOLDING DEVICE” developed by partner, Meister & Cie AG. This platform technology offers medical device manufacturers design freedom and possibilities for device miniaturization.

DSM Biomedical announces partnering with Cerapedics, a privately-held orthobiologics company, to develop and manufacture the next generation peptide enhanced bone graft. The strategic partnership aligns DSM’s regenerative materials capabilities with proprietary synthetic small peptide (P-15) technology developed by Cerapedics.

DSM announces an agreement between Somos® and RP America for the distribution of Somos 3D printing materials in the US market.

DSM announces the collaboration between Somos® and 3D Hubs which provides an online service for customers to obtain accurate 3D printed tooling or molds with quick turn-around time using Somos® PerFORM.

DSM Biomedical announces a new partnership with the Musculoskeletal Transplant Foundation (MTF), a non-profit service organization, to distribute biologic products for use in plastic and reconstructive surgery. The partnership will address the changing needs of hospitals and providers by offering a full suite of biologic products.

Actamax Surgical Materials LLC, a wholly owned subsidiary of DSM, focused on design of bioresorbable medical devices to reduce the burden of post-operative complications for patients undergoing surgery, announces it has received conditional approval of an Investigational Device Exemption (IDE) from the US Food and Drug Administration (FDA). This approval allows Actamax to begin a pivotal clinical trial to evaluate the safety and efficacy of Actamax™ Adhesion Barrier.

Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, announces that it has entered into a collaborative research, development and license agreement with DSM.

DSM Biomedical unveils its Dyneema Purity Black fiber, the first and only black ultra-high molecular weight polyethylene (UHMWPE) medical fiber and the latest innovation in DSM’s Dyneema Purity UHMWPE portfolio.

Actamax Surgical Materials LLC, a wholly owned subsidiary of DSM Biomedical focusing on the development and commercialization of resorbable, biocompatible surgical medical devices that reduce the burden of post-operative complications, announces that it has submitted an Investigational Device Exemption (IDE) to the US Food and Drug Administration (FDA) to study the ActamaxTM Adhesion Barrier in a prospective, randomized controlled trial in gynecological laparoscopic surgery. In pre-submission meetings, Actamax worked constructively with the FDA to discuss questions and concerns and has used FDA’s feedback to determine path forward for its IDE application.

Actamax Surgical Materials LLC, a DSM-DuPont Joint Venture focusing on the development and commercialization of resorbable, biocompatible surgical medical devices, announces that 12 months, long-term clinical follow-up results on its novel adhesion barrier device will be presented at the 45th Global Congress on Minimally Invasive Gynecology in Orlando, Florida this week. The presentation will be by Dr. Geoff Trew, a noted surgeon at London’s Hammersmith Hospital and principal investigator for this study.

DSM announces that its medical-grade Dyneema Purity® fibers fully meet the requirements of ASTM International’s revised standard F2848-16 for medical-grade ultra-high-molecular-weight polyethylene (UHMWPE) yarns. The standard establishes clear requirements for medical-grade UHMWPE yarns, which are an important component to the safety and effectiveness of medical devices.

DSM announces Mr. Eric Teutsch’s appointment as President of DSM Biomedical effective 16 February 2016.

DSM announces that it is teaming up with Teleflex Medical OEM, a global leader in custom sutures and fibers, to host their first joint event highlighting their partnership in the field of high-strength orthopedic sutures. The event will take place during the MD&M West 2016 conference, one of the world’s leading gatherings focused on the latest innovations and technologies in medical devices.

DSM announces a partnership with Vention Medical, a global integrated solutions partner, to provide customers who develop and manufacture coated medical devices with a single-source offering. The partnership offers customers the option to integrate the development, testing and application of DSM’s ComfortCoat® coating into the catheter manufacturing process, eliminating the need to transfer finished products to another supplier for development and coating application services.

DSM announces that the U.S. Food and Drug Administration (FDA) has cleared the Dyneema Purity® Radiopaque Cerclage Cable for use in orthopedic trauma treatments, such as treatment of bone and spine fractures. The Dyneema Purity Radiopaque Cerclage Cable, the first device fully designed and developed by DSM’s Biomedical Polyethylenes Team to receive 510k clearance from the FDA, marks a milestone for the company. DSM sought 510k clearance to support DSM’s customers in bringing their medical devices for use in orthopedic trauma to market.

DSM announces it will increase the capacity at its Hoek van Holland (Netherlands) site for the production of Somos® UV- curable additive manufacturing materials. This investment meets increased customer demand and reflects the growth of the 3D printing industry.

DSM announces a change in the leadership of its DSM Biomedical unit. Christophe Dardel, President DSM Biomedical will pursue his career outside DSM.

DSM announces that it will highlight developments in fiber visualization and low-profile characteristics of its Dyneema Purity® fiber for use in the design of medical devices at the 7th International UHMWPE Meeting on 22 and 23 October in Philadelphia (PA), United States.

DSM announces a new collaboration between Somos®, a world leader in Additive Manufacturing materials, and EnvisionTEC, a world leader in 3D Printing equipment, that opens the door to new applications in the 3D Printing Industry.

DSM finalizes the acquisition of Cubic Tech Corporation. This privately owned company, based in Mesa (Arizona, USA), has specialized for more than 23 years in the custom design, development and production of innovative high performance ultra-lightweight flexible laminates and fabrics — most of them based on Dyneema.

DSM announces a long-term partnership with Groupe Sebbin, a leading manufacturer of breast implants for plastic and reconstructive surgery. Groupe Sebbin will market and distribute DSM’s Meso BioMatrix® Acellular Peritoneum Matrix in Europe and Latin America.

DSM and UMC Utrecht announce succesful-study-with heart valves.

Actamax Surgical Materials LLC, a DSM-DuPont Joint Venture focusing on the development and commercialization of resorbable, biocompatible surgical medical devices, today announced positive safety and efficacy results from the first clinical evaluation of its novel adhesion barrier device.

DSM announces a collaboration with The Artificial Heart Laboratory at the Foundation of Cardiac Surgery Development (FRK) in Zabrze, Poland. FRK will use DSM’s Bionate® II PCU and BioSpan® SPU in its new ventricular assist device, ReligaHeart EXT.

DSM introduces Somos® Precise, the latest material for 3D Printing that is designed to create parts and patterns for high temperature applications requiring exceptional detail resolution. In addition, patterns made with Somos Precise display high levels of dimensional stability even under high humidity conditions.

DSM announces the launch of its Dyneema Purity® Radiopaque fiber, the only radiopaque ultra-high-molecular-weight-polyethylene (UHMWPE) medical fiber in the world. The fiber is the newest addition to DSM’s medical Dyneema Purity fiber portfolio.

DSM announces that Frost & Sullivan, a global growth consulting firm, has honored the Company with the Growth Excellence Leadership Award for Medical Device Coatings. Based on its recent analysis of the Medical Device Coatings market, Frost & Sullivan determined that DSM, through its strong brand recognition and customizable product offering, outperforms its competitors in six selected categories. These include, total customer experience, ownership experience, service experience, above-market growth, growth strategy excellence, and growth sustainability.

DSM announces the launch of its cellular therapy development services. Cellular therapies use a patient’s own cells to improve healing of an injury or disease. DSM develops products that are distributed by major biotechnology and medical device companies into the hands of qualified physicians, who are ultimately responsible for patient care. DSM’s expertise lies in the isolation and concentration of autologous cells at the point of care, along with the technologies to deliver these cells independently or in concert with a variety of other biomaterials to enhance therapeutic effect. DSM offers a complete package of design, development and manufacturing services to create cellular therapy products that are clinically valuable and commercially viable.

DSM announces that Prof. Jian Ping Gong, Professor of the Faculty of Advanced Life Science, Hokkaido University, Japan has been awarded the DSM Materials Sciences Award 2014 in recognition of her exceptional contributions to the advancement of double-network hydrogels and materials sciences.

DSM announces a partnership with Sayan Orthopaedics Ltd. Sayan will use DSM’s Dyneema® Purity fiber in a trauma treatment device, having a combination of different types of Dyneema Purity ultra-high-molecular-weight polyethylene (UHMWPE) fiber only.

DSM announces that the company’s Greenville, North Carolina facility is fully operational, running and qualified. Furthermore, DSM is expanding its Dyneema® Purity fiber portfolio and is commercially launching the thinnest, high-strength, medical-grade UHMWPE fiber available on the market, Dyneema Purity 10 dtex fiber. The fiber will be available in both white and blue.

DSM wins appeal regarding the opposition of patent EP1232198, titled, UV Curable Compositions at the European Patent Office Board of Appeal in Munich, Germany on 17 January 2014. This patent, currently assigned to 3D Systems, Inc., was revoked at the European level, thus allowing for increased development of materials in this field.

DSM announces that the company has launched a new facility to offer coating services for its ComfortCoat® coating technologies. As a strategic partner to medical device makers, DSM offers a full suite of coating application processes, which include coating, testing, packaging, and labeling as well as additional customized processes such as cutting.

DSM announces it has developed a novel ultra-high-molecular-weight polyethylene (UHMWPE) membrane technology. Initial use of the proprietary membrane technology will be in peripheral stent graphs used to treat peripheral artery disease.

DSM announces that the company has partnered with BiO2 Medical, Inc. DSM will supply its proprietary ComfortCoat® lubricious coating and its coating application expertise for use in BiO2 Medical’s Angel Catheter.

DSM brings together thought leaders from across the globe to discuss how cutting-edge 3D printing technologies will transform all areas of manufacturing.

DSM and the Metro Chapter of the Healthcare Businesswomen’s Association (HBA) host an expert panel examining the global and domestic market forces shaping the healthcare landscape and the collaborations that are accelerating the pace of health care innovation and development.

DSM announces that the company has signed a license and supply agreement with spinal implant and surgical systems developer, SpineVision®. License provides SpineVision with clinically proven polyurethane biomaterial to enhance flexibility and compression in posterior lumbar pedicle screw systems.

DSM and AxioMed Spine Corporation announce that they have revised and extended an existing licensing and supply agreement. DSM will supply its proprietary CarboSil® Thermoplastic Silicone-Polycarbonate-urethane material for use in AxioMed’s Freedom® Lumbar and Freedom® Cervical Discs.

DSM announces the expiration of the mandatory waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, for its previously announced tender offer for all outstanding shares of common stock of Kensey Nash Corporation (NASDAQ: KNSY) at a price of $38.50 per share (the “Offer”). This condition of the Offer is thus satisfied.

DSM announces its successful completion of the acquisition of Kensey Nash, through the merger of its subsidiary Biomedical Acquisition Corporation with and into Kensey Nash. As a result of the merger, Kensey Nash is now an indirect wholly owned subsidiary of DSM.

DSM announces that it is contributing proprietary knowledge in the preparation of tailored amino acid-based polymers and offering use of processing facilities that will produce an innovative step change in the sustained delivery of drug molecules. The PANOPTES consortium’s goal is to research and develop novel drug delivery technology for the posterior eye segment. This partnership further validates the innovative properties of DSM’s polyesteramide (PEA) biomaterials as a superior drug delivery technology.

DSM announces a successful collaboration with medical manufacturer EPflex to launch a new set of guidewires with ComfortCoat® hydrophilic coating, a proprietary DSM technology. EPflex will manufacture the guidewires and DSM will provide the coating technology.

DSM and University Medical Center Utrecht announce that they have entered into a collaboration agreement. DSM will contribute its Dyneema Purity fiber technology to enable UMC Utrecht to develop and evaluate a prototype of a non-biological supportive scaffold for the minimally invasive treatment of valvular and vascular diseases.

DSM announces that its VitroStealth non-biofouling coating is used in Afinion®, Axis-Shield's next generation point-of-care diagnostic system. Physicians can use Afinion during the span of an office visit and obtain patient lipid levels within a matter of minutes.

DSM announces that its tender offer to purchase all outstanding shares of common stock of Kensey Nash Corporation (NASDAQ: KNSY) at a price of $38.50 per share was successful.

DSM announces that it has entered into a definitive agreement with Kensey Nash under which DSM would acquire all the outstanding shares of common stock of Kensey Nash through a cash tender offer, followed by a merger with a subsidiary of DSM, for USD 38.50 in cash per share for total enterprise value of approximately USD 360 million. The transaction has been unanimously approved by both DSM’s Supervisory Board and Kensey Nash’s Board of Directors. The agreed price represents a premium of 33% to Kensey Nash’s closing share price of USD 29.01 on May 2, 2012. Subject to customary conditions, the transaction is expected to close around the end of Q2 2012.

DSM announces that its indirect wholly-owned subsidiary, Biomedical Acquisition Corporation, has commenced its previously announced tender offer for all outstanding shares of common stock of Kensey Nash (NASDAQ: KNSY) at a price of $38.50 per share (the “Offer”).